{"id":"NCT00806819","sponsor":"Boehringer Ingelheim","briefTitle":"Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC","officialTitle":"Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2011-06","completion":"2015-12","firstPosted":"2008-12-11","resultsPosted":"2014-11-20","lastUpdate":"2017-02-02"},"enrollment":718,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"Nintedanib (BIBF1120)","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]},{"type":"DRUG","name":"pemetrexed","otherNames":[]},{"type":"DRUG","name":"B12","otherNames":[]},{"type":"DRUG","name":"dexamethasone (or corticosteroid equivalent)","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"dexamethasone (or corticosteroid equivalent)","otherNames":[]},{"type":"DRUG","name":"B12","otherNames":[]},{"type":"DRUG","name":"Folic Acid","otherNames":[]},{"type":"DRUG","name":"B12","otherNames":[]},{"type":"DRUG","name":"dexamethasone (or corticosteroid equivalent)","otherNames":[]},{"type":"DRUG","name":"Folic Acid","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"Folic Acid","otherNames":[]},{"type":"DRUG","name":"Nintedanib (BIBF1120)","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]}],"arms":[{"label":"nintedanib (BIBF1120) plus pemetrexed","type":"EXPERIMENTAL"},{"label":"Placebo plus pemetrexed","type":"PLACEBO_COMPARATOR"},{"label":"nintedanib (BIBF1120) monotherapy","type":"EXPERIMENTAL"},{"label":"pemetrexed monotherapy","type":"ACTIVE_COMPARATOR"},{"label":"placebo monotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.","primaryOutcome":{"measure":"Progression Free Survival (PFS) as Assessed by Central Independent Review","timeFrame":"From randomisation until cut-off date 9 July 2012","effectByArm":[{"arm":"Nintedanib Plus Pemetrexed","deltaMin":4.4,"sd":null},{"arm":"Placebo Plus Pemetrexed","deltaMin":3.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0435"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":163,"countries":["United States","Argentina","Australia","Bosnia and Herzegovina","Brazil","Canada","Chile","Colombia","Ecuador","Germany","Hong Kong","Hungary","Ireland","Latvia","Malaysia","Mexico","Moldova","Netherlands","New Zealand","North Macedonia","Panama","Peru","Philippines","Poland","Romania","Serbia","South Korea","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["28184431"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":104,"n":347},"commonTop":["Nausea","Fatigue","Alanine aminotransferase increased","Aspartate aminotransferase increased","Decreased appetite"]}}